Federal Agencies Secretly Test Anthropic's AI Despite Trump Administration Ban 
Qantas Raises Fuel Cost Forecast Amid Middle East Oil Crisis 
ASML Raises 2026 Revenue Outlook as AI Chip Demand Surges 
Tesla's Terafab: AI Chip Factory Eyes Taiwan's Semiconductor Talent 
DEEPX Partners with Hyundai to Power Next-Gen AI Robots Ahead of IPO 
Samsung Races to Deliver Next-Gen HBM4E Memory Samples to Nvidia 
Elon Musk's Terafab Foundry Courts Top Chipmaking Giants for AI Self-Sufficiency Push 
Hermès Q1 2026 Sales Miss Expectations Amid Iran War and China Slowdown 
KKR's $820M Investment Fuels Samsung SDS AI Expansion, Sending Group Shares Soaring 
AEVEX Raises $320 Million in IPO Amid Surging Defense Sector Demand 
NiSource Signs Long-Term Energy Deals with Alphabet and Amazon to Power Indiana Data Centers 
Uber Bets Big on Autonomous Vehicles with $10 Billion Commitment 
Iran War Drives Asia's Plastic Crisis — and a Green Packaging Boom 
Goldman Sachs FICC Revenue Falls 10% Amid Iran War Market Volatility 
Federal Judge Dismisses DOJ Lawsuit Attempting to Block Hawaii's Climate Case Against Oil Giants 
Elliott Investment Takes ~3% Stake in Daikin, Pushes for Buybacks and Strategic Overhaul 
Texas AG Investigates Lululemon Over "Forever Chemicals" in Activewear 
LEXINGTON, Mass., June 01, 2017 -- Curis, Inc. (NASDAQ:CRIS), a biotechnology company focused on the development and commercialization of innovative and effective therapeutics for the treatment of cancer, today announced that Ali Fattaey, Ph.D., President and Chief Executive Officer, will present at the Jefferies Healthcare Conference on June 7, 2017, at 3 p.m. EDT in New York City.
A corresponding webcast of the presentation can be accessed by visiting:
http://www.wsw.com/webcast/jeff105/cris
The webcast will be archived shortly after the live event and available for 30 days following the conference, and also available for 30 days on the Investor Relations section of the Curis website at www.curis.com.
About Curis
Curis is a biotechnology company focused on the development and commercialization of innovative and effective drug candidates for the treatment of human cancers, including its lead candidate, CUDC-907 that is being investigated in clinical studies in patients with lymphomas and solid tumors. Curis is also engaged in a broad collaboration with Aurigene in the areas of immuno-oncology and precision oncology. As part of this collaboration, Curis has exclusive licenses to oral small molecule antagonists of the PD-1 and VISTA pathways, including PD-L1/VISTA antagonist CA-170, as well as to molecules designed to inhibit the IRAK4 kinase, including CA-4948. CA-170 is currently undergoing testing in a Phase 1 trial in patients with advanced solid tumors and lymphomas. Curis is also party to a collaboration with Genentech, a member of the Roche Group, under which Genentech and Roche are commercializing Erivedge® for the treatment of advanced basal cell carcinoma, and are further developing Erivedge in other diseases including idiopathic pulmonary fibrosis and myelofibrosis. For more information, visit Curis' website at www.curis.com.
For More Information: James E. Dentzer Chief Financial Officer & Chief Administrative Officer Curis, Inc. 617-503-6500 [email protected] Media Contact David Schull Russo Partners (212) 845-4271 [email protected]
